Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Gains from Investment Securities (2025)

Maze Therapeutics has reported Gains from Investment Securities over the past 1 years, most recently at $5.7 million for Q3 2025.

  • Quarterly Gains from Investment Securities changed N/A to $5.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Sep 2025, changed N/A year-over-year, with the annual reading at $5.3 million for FY2024, N/A changed from the prior year.
  • Gains from Investment Securities was $5.7 million for Q3 2025 at Maze Therapeutics, up from $5.3 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $5.7 million in Q3 2025 and troughed at $5.3 million in Q1 2025.